Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long?. Issue 6 (3rd December 2022)

• Record Type: Journal Article
• Authors: Bassetti, Matteo; Vena, Antonio; Labate, Laura; Giacobbe, Daniele R.
• Is Part Of: Current opinion in infectious diseases. Volume 35:Issue 6(2022)
• Page Start: 568
• Page End: 574
• Publication Date: 2022-12-03
• Subjects: antimicrobial resistance -- antimicrobial stewardship -- cefiderocol -- ceftazidime/avibactam -- ceftolozane/tazobactam -- imipenem/relebactam -- meropenem/vaborbactam -- rapid diagnosis; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Review Literature -- Periodicals; 616.905
• DOI: 10.1097/QCO.0000000000000884
• Languages: English
• ISSNs: 0951-7375

Abstract

Abstract : Purpose of review: To discuss empirical therapy for severe infections due to Gram-negative bacteria with difficult-to-treat resistance (GNB-DTR) in current clinical practice, focusing in particular on the positioning of novel therapeutic agents and rapid diagnostic tests. Recent findings: The current era of novel agents active against GNB-DTR and showing differential activity against specific determinants of resistance is an unprecedented scenario, in which the clinical reasoning leading to the choice of the empirical therapy for treating severe GNB-DTR infections is becoming more complex, but it also allows for enhanced treatment precision. Summary: Novel agents should be used in line with antimicrobial stewardship principles, aimed at reducing selective pressure for antimicrobial resistance. However, this does not mean that they should not be used. Indeed, excesses in restrictive uses may be unethical by precluding access to the most effective and less toxic treatments for patients with severe GNB-DTR infections. Given these premises (the 'how'), empirical treatment with novel agents should be considered in all patients with risk factors for GNB-DTR and severe clinical presentation of acute infection (the 'when'). Furthermore, empirical novel agents should preferably be continued only for a few hours, until de-escalation, modification, or confirmation (as targeted therapy) is made possible by the results of rapid diagnostic tests (the 'how long').